δ-selective inhibitors (idelalisib, duvelisib) manifest immune-mediated toxicities, with idelalisib-treated SLL/FL patients experiencing grade ≥ 3 neutropenia (25%), hepatotoxicity (ALT elevation: 18%), and colitis (14%), while duvelisib shows higher rates of inflammatory complications (colitis: 12%). Here, GPT is linked to colitis.